Sirtuin activator supplements in women with overweight or obesity
Tests sirtuin activator supplements against placebo for metabolism in women with overweight.
Plain-language title generated from the registry record
Registry title: Supplementation With Sirtuin Activators in Women With Increased Body Weight
Key facts
- Where
- Poznan, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 65 years old?
Source: NCT07245979, who can take part
Where in Poland
- Poznań University of Life SciencesPoznan, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Poznan University of Life Sciences
- Trial code
- NCT07245979
- Record updated
- 22 May 2026
- Original description
The goal of this clinical trial is to learn if the six-month supplementation with sirtuin activators can affect metabolism in 40-to-65-year old women with increased body weight. The main questions it aims to answer are:Read full original descriptionShow less
Assessment of the Effect of Sirtuin Activator Supplementation on Cellular, Metabolic and Anthropometric Parameters in Women
The goal of this clinical trial is to learn if the six-month supplementation with sirtuin activators can affect metabolism in 40-to-65-year old women with increased body weight. The main questions it aims to answer are:
Does sirtuin activators affect lipid and carbohydrate metabolism? Does sirtuin activators affect oxydative stress, immune functions and cell ageing?
Researchers will compare sirtuin activators to a placebo (a look-alike substance that contains no drug) to see if drug sirtuin activators works to improve metabolic status.
Participants will:
Take sirtuin activators or a placebo every day for 6 months. Visit the university once every 3 months for checkups and tests.
Inclusion: females; age: 40-65 years; overweight or obese: BMI >25 kg/m2.
Exclusion: sirtuin activators administration for 3 months prior to study; receiving pharmacotherapy to treat obesity, diabetes or hyperlipidemia; post-bariatric surgery; diabetes; cancer; chronic kidney, liver or autoimmune diseases; males; BMI < 25 kg/m2; pregnancy or breastfeeding; recent dieting or being on calorie restricted diet; alcohol addiction.